<div class="subscription-widget-wrap-editor"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading Stock Analysis Compilation! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input class="email-input" name="email" tabindex="-1" type="email" /><input class="button primary" type="submit" value="Subscribe" /><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><div><hr /></div><h3>🚀 Beyond this week’s pitches: the full searchable archive of 3,000+ hedge-fund pitches across 300+ funds lives on the site. </h3><p class="button-wrapper"><a class="button primary" href="https://www.hfbestideas.com/pricing?utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=cta-top"><span>Start a 7-day free trial</span></a></p><div><hr /></div><p>🔹 Amphenol (APH US) by Brasada CM<br />🔹 Amphenol (APH US) by Guinness Sustainable Energy Fund (Guinness Global Investors)<br />🔹 ASML Holding N.V. (ASML NA) by Bell Global Equities Fund<br />🔹 AstraZeneca PLC (AZN LN) by Bell Global High Conviction Fund<br />🔹 CrowdStrike (CRWD US) by Jacob Funds Management Commentary<br />🔹 Elite Material (2383 TT) by ClearBridge Investments Emerging Markets Strategy<br />🔹 Encompass Health Corporation (EHC US) by TAMIM Fund: Global High Conviction Unit Class<br />🔹 Fastenal Company (FAST US) by Brasada CM<br />🔹 Games Workshop (GAW LN) by Guinness Pan-European Equity Income Fund<br />🔹 GE Vernova (GEV US) by Fundsmith Equity Fund<br />🔹 HCA Healthcare, Inc. (HCA US) by Bell Global Equities Fund<br />🔹 Infratil (IFT NZ) by Guinness Global Real Assets Fund<br />🔹 Kaspi.kz (KSPI US) by Vlatava fund<br />🔹 Luotea Oyj (LUO1V FH) by Protean Funds Partner Letter<br />🔹 Mastercard (MA US) by Fundsmith Equity Fund<br />🔹 Netflix (NFLX US) by Fundsmith Equity Fund<br />🔹 NexGen Energy (NXE US) by Goehring & Rozencwajg Natural Resource Market Commentary<br />🔹 NextEra Energy (NEE US) by Guinness Sustainable Energy Fund (Guinness Global Investors)<br />🔹 NICE Information Service (030190 KS) by Ennismore Global Smaller Companies Fund<br />🔹 NXP Semiconductors N.V. (NXPI US) by Guinness Sustainable Energy Fund<br />🔹 Otis (OTIS US) by ClearBridge Investments Dividend Strategy<br />🔹 Otis Worldwide Corporation (OTIS US) by Bell Global Emerging Companies Fund<br />🔹 Pan Pacific International Holdings Corporation (7532 JP) by Bell Global Emerging Companies Fund<br />🔹 Premium Brands Holdings Corp (PBH CN) by Alta Fox<br />🔹 Robinhood (HOOD US) by Jacob Funds Management Commentary<br />🔹 Sensata Technologies Holding (ST US) by Guinness Sustainable Energy Fund (Guinness Global Investors)<br />🔹 SK Square (402340 KS) by ClearBridge Investments Emerging Markets Strategy<br />🔹 Sprott Physical Uranium Trust (U.UN CN) by Goehring & Rozencwajg Natural Resource Market Commentary<br />🔹 Tesla, Inc. (TSLA US) by Baron Capital Long-Only Growth Strategy<br />🔹 The TJX Companies (TJX US) by Fundsmith Equity Fund<br />🔹 Uber (UBER US) by Fundsmith Equity Fund<br />🔹 Veeva Systems (VEEV US) by Fundsmith Equity Fund<br />🔹 Vir Biotechnology (VIR US) by Jacob Funds Management Commentary<br />🔹 Visa (V US) by Vlatava fund<br />🔹 Watches of Switzerland Group (WOSG LN) by Night Watch Investment Management Global Value Strategy</p><div><hr /></div><h3>Amphenol ($APH US)</h3><p><strong>Fund:</strong> Brasada CM</p><p><strong>Thesis:</strong> Amphenol is a mission-critical interconnect leader with switching costs, decentralized execution, AI-driven growth, and long-term electrification and digitization tailwinds.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=8vLSNCFYUbbh&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Amphenol Corp (APH) Amphenol is one of the world’s largest manufacturers of connectors, sensors, and interconnect systems, essentially producing the nervous system for modern electronics. The company designs solutions that allow power, signal, and data to flow reliably across demanding applications. Rather than selling off-the-shelf commodities, Amphenol acts as a crucial design partner, engineering the vast majority of its 500,000 SKUs as custom or semi-custom solutions tailored to the exact mechanical, thermal, or electrical requirements of its customers. What makes Amphenol a high-quality business lies in its production of mission-critical components that represent a very small percentage of a customer’s total cost of goods. Because the cost of failure is exceptionally high, whether in a commercial aircraft flying at 40,000 feet or a 1,000-volt EV battery, OEMs face significant switching costs and are reluctant to change suppliers once a component is proven reliable. This dynamic is further reinforced by a highly decentralized operating structure where general managers run their business units autonomously, enabling rapid, localized responses to customer needs. Additionally, the company is diversified across eight major end markets, with no single sector accounting for more than 25% of sales, which acts as a powerful shock absorber during cyclical downturns. Currently, Amphenol is experiencing a supercharged growth cycle driven by the infrastructure buildout in AI. For example, high-speed AI servers designed to train large language models require 50 to 100 times more connector content than traditional enterprise servers to handle enormous power distribution and signal integrity needs. As major hyperscalers like AWS, Azure, and GCP build out their data center clusters, Amphenol provides critical high-speed connectors, fiber assemblies, and backplane systems, effectively acting as the system that allows data to move at hundreds of gigabits per second. Looking forward, Amphenol’s growth runway is also underpinned by the long-term megatrends of electrification and digitization. Whenever an application becomes smarter or more electronic, from factory automation systems and EV powertrains to broadband networks, Amphenol’s content per unit naturally increases, creating a persistent flywheel of organic growth. Furthermore, their market remains fragmented and provides a massive ongoing opportunity for Amphenol to execute its proven, countercyclical M&A playbook on top.</p><p><a href="https://www.hfbestideas.com/?q=APH+US&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-aph-us">Access our full research database on Amphenol</a></p><div><hr /></div><h3>Amphenol ($APH US)</h3><p><strong>Fund:</strong> Guinness Sustainable Energy Fund (Guinness Global Investors)</p><p><strong>Thesis:</strong> Amphenol participates in electrical equipment niches that support electrification and grid build-out across many end markets.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=9mSseRqLunt9&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>A key theme in the portfolio, at c.40% weight, is that of electrical equipment (covering both grid equipment and electrical equipment classifications), where we own a number of companies that facilitate the electrification of energy demand and the build-out of the electrical grid. Holdings such as Eaton, Schneider Electric, Amphenol and Legrand participate in various niches in the design, manufacturing and servicing of electrical products across low, medium and high voltage applications, for a wide range of end markets.</p><p><a href="https://www.hfbestideas.com/?q=APH+US&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-aph-us">Access our full research database on Amphenol</a></p><div><hr /></div><h3>ASML Holding N.V. ($ASML NA)</h3><p><strong>Fund:</strong> Bell Global Equities Fund</p><p><strong>Thesis:</strong> ASML is a semiconductor equipment leader with strong operating results, earnings upgrades, and a robust order book.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=l48waO1jIfbQ&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>We also re-established a position in a couple of previously held stocks which had previously been sold for valuation reasons, including ASML and HCA Healthcare. In the case of ASML, the Dutch semiconductor equipment manufacturer, the stock had modestly underperformed since our exit despite continuing to deliver strong operating results and material earnings upgrades. As a result, the valuation multiple has compressed at the same time that the company’s robust order book has provided increased confidence in the medium-term earnings trajectory, which we believe warranted re-initiating the position.</p><p><a href="https://www.hfbestideas.com/?q=ASML+NA&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-asml-na">Access our full research database on ASML Holding N.V.</a></p><div><hr /></div><h3>🔓 Unlock the full research database</h3><p>This week’s ideas are a sample. The real edge is the <strong>full searchable archive</strong>: <strong>The Associate ($19/mo)</strong> gives you every pitch we’ve indexed — 3,000+ across 300+ funds — searchable by fund, sector or ticker, plus the entire quarterly-letter archive. The weekend of PDF-hunting, already done for you.</p><p><strong>The Rainmaker ($29/mo)</strong> adds <strong>Warren AI</strong> to ask questions across the whole corpus in plain English.</p><p class="button-wrapper"><a class="button primary button-wrapper" href="https://www.hfbestideas.com/pricing?utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=cta-top"><span>Start a 7-day free trial</span></a></p><div><hr /></div><h3>AstraZeneca PLC ($AZN LN)</h3><p><strong>Fund:</strong> Bell Global High Conviction Fund</p><p><strong>Thesis:</strong> AstraZeneca is a global biopharmaceutical company with a diversified pipeline, strong execution, and attractive long-term compounder characteristics.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=29HX3R75pTZr&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>During April we established a position in global biopharmaceutical company AstraMeneca, where we are attracted to the company’s diversified and high-quality pipeline, underpinning a strong outlook for sustainable earnings growth over the medium term. The company has built a broad portfolio across oncology, rare diseases, and biopharmaceuticals, reducing reliance on any single asset and providing meaningful pipeline optionality over the medium term. Management has demonstrated consistent execution in both R&D and commercialisation, translating innovation into durable growth. Importantly, AstraMeneca has a well-diversified revenue base and manageable patent exposure, supporting visibility on earnings and cash flow. Recent results were solid, reinforcing confidence in the underlying trajectory. The stock has, however, pulled back following concerns around camizestrant, a breast cancer pipeline asset, after a negative FDA advisory committee vote. While this reduces the probability of approval in that indication, we do not view it as material to the broader investment case given the depth and diversity of the pipeline. Overall, we see AstraMeneca as a high-quality compounder, with recent weakness providing an opportunity to initiate exposure at a more attractive valuation.</p><p><a href="https://www.hfbestideas.com/?q=AZN+LN&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-azn-ln">Access our full research database on AstraZeneca PLC</a></p><div><hr /></div><h3>CrowdStrike ($CRWD US)</h3><p><strong>Fund:</strong> Jacob Funds Management Commentary</p><p><strong>Thesis:</strong> CrowdStrike is a cloud-native cybersecurity leader positioned to secure autonomous AI agents and enterprise adoption of agentic AI.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=28EUfNriJm3K&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>CrowdStrike is a leading cloud-native cybersecurity company delivering endpoint protection, threat intelligence, and incident response through its Falcon platform. Because CrowdStrike already operates as a real-time control layer where autonomous AI agents will need to be secured, it can monitor both human and non-human actors within the same architecture. Enterprises will need to upgrade their security requirements from only endpoint and perimeter concerns to protecting themselves from agents that will need to have access to their systems, making CrowdStrike a critical enabler of safe enterprise adoption of agentic AI.</p><p><a href="https://www.hfbestideas.com/?q=CRWD+US&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-crwd-us">Access our full research database on CrowdStrike</a></p><div><hr /></div><h3>Elite Material ($2383 TT)</h3><p><strong>Fund:</strong> ClearBridge Investments Emerging Markets Strategy</p><p><strong>Thesis:</strong> Elite Material is a structural AI infrastructure enabler with pricing power and high barriers to entry.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=rMjUxHuBSbxE&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Elite Material, a provider of copper-clad materials used in circuit boards, has transitioned from a cyclical electronics materials supplier into a structural enabler of AI infrastructure with a competitive advantage in technology and manufacturing consistency. As AI systems become more complex and performance sensitive, Elite’s products become mission critical, underpinning sustainable pricing power and high barriers to entry.</p><p><a href="https://www.hfbestideas.com/?q=2383+TT&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-2383-tt">Access our full research database on Elite Material</a></p><div><hr /></div><h3>Encompass Health Corporation ($EHC US)</h3><p><strong>Fund:</strong> TAMIM Fund: Global High Conviction Unit Class</p><p><strong>Thesis:</strong> Encompass Health is the leading US inpatient rehabilitation provider, supported by demographics, scarce capacity, strong margins, and a reasonable valuation.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=sSgS4xffK16b&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Encompass Health Corporation (NYSE: EHC) Encompass Health operates the largest network of inpatient rehabilitation hospitals in the United States and Puerto Rico, providing specialised post acute care for patients recovering from major injury or illness. Stroke. Spinal cord injury. Hip replacement. Cardiac surgery. The kinds of clinical pathways where intensive rehabilitation makes a measurable difference to long term outcomes, and where the alternative to specialist inpatient care is poorer recovery, longer hospital stays, and higher overall costs to the health system. The investment case is built on three structural drivers that are unlikely to reverse. American demographics, with the over 65 population continuing to grow at roughly double the rate of the total population. The continued shift toward post acute specialisation, as health systems realise that acute care hospitals are an expensive place to convalesce. And the genuine scarcity of high quality inpatient rehabilitation capacity in many US markets, which keeps occupancy rates high and gives Encompass meaningful pricing leverage with both Medicare and private insurance. The recent share price weakness has been driven by two specific concerns. The first is reported pressure from large health insurance companies pushing for more aggressive pricing rebates on post acute services. The second is the broader uncertainty around Medicare policy under the current administration, with Robert Kennedy Jr’s department signalling potential changes to several elements of the program. Both of these concerns are real. Neither, in our view, breaks the long term thesis. The reason is that Encompass operates in a structurally undersupplied part of the US healthcare system. The company is currently expanding capacity, with seven new hospitals planned. Occupancy rates are high. Margins are healthy. EBITDA margins reached 23.3 per cent in FY25 and are expected to remain above 21 per cent through the cycle. EBIT margins are running close to 18 per cent. And critically, the company has been raising guidance through 2026, not lowering it. EBITDA and EPS forecasts have moved up, even as the share price has moved down. That is the kind of dislocation that creates opportunities for investors willing to look past the immediate news flow. Valuation has compressed accordingly. Encompass trades at roughly 17 times current year earnings and around 16 times next year, with a price to sales ratio of just 1.6 times. For a healthcare services business with double digit revenue growth, expanding margins, raising guidance, and a clear path to capacity expansion, this is not a demanding multiple. The 12 month analyst price target average sits at $140.50 against a current share price around $103. The dividend yield is modest at 0.74 per cent but the company has a long record of capital return through buybacks and selective dividend increases. We do not pretend that the Medicare risk is zero. Policy changes are genuinely difficult to forecast, and the rebate pressure from insurers is a real margin headwind. But the business is structurally well positioned, the management team has navigated multiple Medicare cycles, the balance sheet is reasonable, and the demographic backdrop is undeniable. At a time when the technology sector demands ever more aggressive growth forecasts to justify multiples that already assume miracles, owning a healthcare business with raising guidance at 17 times earnings looks rather sensible by comparison. We particularly like the contrast with the so called Magnificent Seven, where we now have virtually no exposure on valuation grounds. Encompass offers a different profile entirely: structural growth, dependable margins, a real asset base, and a multiple that allows for ordinary disappointments without permanent capital loss.</p><p><a href="https://www.hfbestideas.com/?q=EHC+US&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-ehc-us">Access our full research database on Encompass Health Corporation</a></p><div><hr /></div><h3>Fastenal Company ($FAST US)</h3><p><strong>Fund:</strong> Brasada CM</p><p><strong>Thesis:</strong> Fastenal is a mission-critical industrial supply-chain partner with pricing power, decentralized execution, reshoring tailwinds, and long-term expansion opportunities.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=8vLSNCFYUbbh&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Fastenal Company (FAST) Fastenal distributes a wide array of products including fasteners, tools, safety equipment, and janitorial supplies, but at its core Fastenal is an outsourced procurement and supply chain partner for the industrial sector, helping to seamlessly manage customer inventory. Fastenal embeds itself within its customers’ operations through local branches, automated industrial vending machines, FASTBins equipped with RFID technology, and dedicated Onsite locations where full-time Fastenal employees work directly on the customer’s manufacturing floor. By handling the complexities of sourcing and replenishment, Fastenal ensures parts are always available, allowing clients to focus on their core competencies without the risk of costly production delays caused by a missing screw. What makes Fastenal a high-quality business is that their customers have come to depend on them for cheap, mission critical parts – any delay or having the wrong type of fastener in inventory can mean millions of dollars in costs for the manufacturers in the form of slowdowns, shutdowns, poor product quality, or recalls. If you’re missing a $0.30 screw on a $10K or $10M machine, you’re just not shipping that machine, and if you have too many of those screws laying around, you’re likely wasting space and money. As such, Fastenal commands premium pricing power, high returns on capital, and reoccurring revenue. On top of that, Fastenal runs a decentralized, highly frugal culture that empowers branch managers to run their operations like entrepreneurs, heavily tying their incentives to localized growth and strict margin discipline. With roughly 70% of its revenue derived from manufacturing businesses, any acceleration in industrial activity, as we have recently seen with the ISM numbers looking better than they have in years, drives higher consumption of the components that Fastenal supplies. Additionally, the ongoing trend of supply chain reshoring acts as another secular tailwind. As companies bring production back to North America, the construction of new domestic factories and the subsequent increase in localized industrial production expand Fastenal’s addressable market. Furthermore, since reshoring often exacerbates domestic labor shortages, manufacturers are increasingly reliant on Fastenal to outsource their supply chain and inventory management functions. Looking ahead, Fastenal’s long-term growth runway remains vast. The company holds just a single digit percent market share in the highly fragmented U.S. fastener market and generates only 17% of its revenue internationally, leaving significant room for geographic and category expansion. Domestically, the company estimates it can expand its footprint of Onsite locations from 2,000 today to 15,000 over time. Lastly, in addition to traditional manufacturing, Fastenal is benefiting from the AI infrastructure buildout. The construction and maintenance of hyperscale data centers demand an enormous volume of structural components, server racks, cooling systems, power distribution units, and more. Fastenal is a supplier of the more mundane, but critical “nuts and bolts” to many of the companies that manufacture these products as well as physically putting vending machines onsite during data center construction.</p><p><a href="https://www.hfbestideas.com/?q=FAST+US&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-fast-us">Access our full research database on Fastenal Company</a></p><div><hr /></div><h3>Games Workshop ($GAW LN)</h3><p><strong>Fund:</strong> Guinness Pan-European Equity Income Fund</p><p><strong>Thesis:</strong> Games Workshop is a high-quality Warhammer business with strong pricing power, loyal customers, high cash generation, and growth runway.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=KGFGACwvOqq5&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>Games Workshop is the Nottingham-based creator of Warhammer. It designs and manufactures its miniatures in-house, sells them worldwide through its own stores, online and independent retailers, and licenses the Warhammer universe to third parties at high margins. It has everything we look for in our quality bucket: a high cash flow return on investment (CFROI of over 20%), a prudent, conservative management team that distributes only genuinely surplus cash and keeps the balance sheet healthy (net debt/EBITDA of -0.4x), and a clear customer value proposition. Retail is a tough sector, but Games Workshop has carved out a real niche, with a loyal community and the kind of pricing power few retailers enjoy; enough to push through price rises this year to offset US tariffs without denting volumes. We see a clear runway for further growth in both the core hobby and the licensing pipeline and we believe that a free cash flow yield over 4.5% is an attractive entry point for a company with a net cash balance sheet, free cash flow per share compounding at close to 29% a year over three years, and a dividend that yields around 2.7% and has grown at close to 19% a year over five years.</p><p><a href="https://www.hfbestideas.com/?q=GAW+LN&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-gaw-ln">Access our full research database on Games Workshop</a></p><div><hr /></div><h3>GE Vernova ($GEV US)</h3><p><strong>Fund:</strong> Fundsmith Equity Fund</p><p><strong>Thesis:</strong> GE Vernova builds and services gas turbines and grid equipment, benefiting from high switching costs, a large backlog, and exposure to grid upgrades, AI data centers, and SMRs.</p><p><strong>Source:</strong> <a href="https://www.hfbestideas.com/letters?open=s7VsSnMpbLnJ&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=letter-source">Read the original letter ↗</a></p><p><strong>Analysis:</strong></p><p>GE Vernova – GE Vernova builds and services the gas turbines and electrical grid equipment that power the modern world. Its competitive ‘moat’ stems from the scale and high switching costs of energy infrastructure: once its turbines are installed, customers are locked into high-margin, inflation-protected service contracts for decades. Unlike elevators and escalators, these generators cannot be serviced by independent providers because all the technology and materials are proprietary. GE Vernova’s equipment generates approximately a third of the world’s total electricity. Future growth depends on upgrading ageing power grids to handle the high voltages needed to deliver power from where it is produced to where it is needed, and on increasingly ‘behind-the-meter’ power generation at AI data centres. That growth is also fairly predictable as the current order backlog is $163bn (4x 2025 revenues). They are also the global leader in small modular nuclear reactors (SMRs). They currently have the only commercial SMR project (BWRX-300) under construction in the Western world, with the first deployment in Canada expected to be finished by 2030. ROIC: ~20% but rising rapidly, FCF yield: 2.6%.</p><p><a href="https://www.hfbestideas.com/?q=GEV+US&page=1&utm_source=substack&utm_medium=newsletter&utm_campaign=weekly_digest&utm_content=db-gev-us">Access our full research database on GE Vernova</a></p>
<p>
<a href="https://hfbestideas.substack.com/p/35-new-pitches-found-in-hedge-fund">
Read more
</a>
</p>